The Story of The Cigna Group

A structural look at how a century-old insurer, blocked from consolidating horizontally, reinvented itself by absorbing the pharmacy supply chain instead.

Introduction

The Cigna Group (CI) occupies a distinctive structural position among large American healthcare companies. It is not primarily a government-program insurer like UnitedHealth (UNH) or Humana (HUM). It is not a retail pharmacy chain that absorbed an insurer like CVS Health (CVS) did with Aetna. It is not a Blue Cross licensee operating state-by-state like Elevance Health (ELV).

Cigna is an employer-focused health benefits company that transformed itself into a healthcare services conglomerate through a single, defining acquisition — the $67 billion purchase of Express Scripts in 2018. That transaction did not merely add a business line.

It restructured the company's economic center of gravity, shifting the majority of revenue and operating income from insurance underwriting to pharmacy benefit management and health services.

Understanding Cigna requires seeing two things simultaneously. First, the company's long history as a property, casualty, and health insurer — a trajectory shaped by mergers, divestitures, and strategic narrowing over more than two centuries. Second, the structural logic of combining health insurance with pharmacy benefit management — a form of vertical integration that creates data linkages, cost management levers, and revenue streams that neither business produces independently. The Express Scripts acquisition was not opportunistic. It was the structural response to a managed care industry where standalone insurance was becoming a lower-margin, more commoditized business, and where control over drug spending — the fastest-growing component of healthcare cost — offered both economic advantage and strategic differentiation. The PBM sits at the intersection of pharmaceutical manufacturers, pharmacies, employers, and patients — a position of informational leverage that generates value precisely because it mediates the flow of drugs and money between parties who cannot easily transact without intermediation.

The Cigna arc also reveals something about the limits of consolidation in American healthcare. The failed merger with Anthem in 2017 and the abandoned acquisition of Humana in 2024 bracket the Express Scripts deal and demonstrate that horizontal mergers among large insurers face political and regulatory resistance that vertical integration does not — at least not to the same degree. The pattern is structural: Cigna could not grow by absorbing a rival insurer, so it grew by absorbing the pharmacy supply chain instead. The question is whether that structural choice creates durable advantage or introduces new fragilities that horizontal scale would not have produced. The answer depends on how the regulatory environment around PBM transparency evolves, how biosimilar competition reshapes specialty drug economics, and whether the employer-focused insurance model can sustain growth in an aging society where government health programs are the dominant source of coverage expansion.

The Long-Term Arc

How did Cigna's insurance lineage form over two centuries (1792 - 1990s)?

Cigna's corporate ancestry extends to 1792, when the Insurance Company of North America — one of the first stock insurance companies in the United States — was chartered in Philadelphia. The company underwrote marine insurance for the ships that carried American trade across the Atlantic, and it grew over the next century into a diversified property and casualty insurer. Separately, the Connecticut General Life Insurance Company was founded in 1865 in Hartford, building a business centered on group life and health insurance for employees of large corporations. For over a century, these two companies evolved along parallel but distinct paths — one focused on property-casualty risk, the other on employee benefits and group coverage.

The name "Cigna" emerged in 1982 from the merger of Connecticut General and INA Corporation (the successor to the Insurance Company of North America). The combination was intended to create a diversified financial services company with capabilities spanning property-casualty insurance, life insurance, health benefits, pension management, and investment services. The strategic vision was broad — a one-stop financial services conglomerate in the model that was fashionable during the early 1980s. The reality proved more complicated. Combining two large organizations with different cultures, different products, and different risk profiles created integration challenges that persisted for years.

The post-merger decades were marked by the kind of strategic ambiguity that characterizes many insurance conglomerates. Cigna operated across multiple insurance lines with varying degrees of profitability and strategic coherence. The property-casualty business generated volatile results — exposure to catastrophic losses, environmental liability claims, and asbestos-related litigation created periods of significant financial strain that consumed management attention and capital that might otherwise have been deployed into growth businesses. The health benefits business, while growing, competed against increasingly large rivals in a managed care market that was consolidating rapidly around UnitedHealth Group, Aetna, and the Blue Cross Blue Shield system.

The structural question during this period was whether Cigna's diversification across insurance lines represented a strength or a distraction. The answer came through a series of divestitures that unfolded over roughly two decades. Cigna sold its individual life insurance and annuity business to Lincoln National Corporation. It exited its property-casualty reinsurance operations after sustaining substantial losses from environmental and asbestos claims. It separated and ultimately divested its investment management capabilities. Each divestiture narrowed the company's focus and concentrated resources on the health benefits business — the segment with the largest addressable market, the most predictable revenue characteristics, and the most defensible competitive position. By the early 2000s, Cigna had effectively transformed from a diversified insurance conglomerate into a health benefits company, though the transformation was gradual enough that it received less attention than the dramatic mergers reshaping the managed care landscape around it.

How did Cigna's employer-focused model differ from its competitors (2000s - 2015)?

While competitors pursued government program enrollment — Medicare Advantage, Medicaid managed care, individual exchange plans under the Affordable Care Act — Cigna built its identity around employer-sponsored health insurance. Large self-funded employers, who bear the financial risk of their employees' medical claims and hire insurers to administer benefits and manage provider networks, became Cigna's core customer base. This strategic orientation was distinctive and deliberate. It meant that Cigna's revenue was disproportionately tied to corporate benefits departments rather than government reimbursement rates or individual consumer purchasing decisions.

The employer-focused model created specific structural characteristics that distinguished Cigna from its peers. Administrative services fees — rather than fully-insured premiums — constituted a significant portion of revenue. In a self-funded arrangement, the employer pays the actual medical claims; Cigna earns fees for building and maintaining the provider network, processing claims, managing utilization, and providing data analytics to help employers understand and control their healthcare spending. Medical loss ratios — the metric that dominates analysis of traditional health insurers — mattered less when the employer bore the underwriting risk and Cigna earned fees for administrative and clinical services. The customer relationship was B2B rather than B2C, which meant that sales cycles were longer, switching costs were higher, and account retention depended on demonstrating measurable value — lower medical cost trends, better employee health outcomes, superior data analytics, effective specialty cost management — rather than on brand recognition or retail distribution reach.

The self-funded employer model also created a natural data asset. Because Cigna processed claims for millions of employees across thousands of large employers, the company accumulated detailed medical utilization data — which procedures were performed, which providers delivered the best outcomes at the lowest cost, which chronic conditions drove the most spending, which interventions reduced downstream claims. This data, properly analyzed, could inform network design, clinical program development, and cost management strategies in ways that created value for employer clients. The data advantage compounded with scale: more members meant more data, which meant better analytics, which meant more effective cost management, which attracted more employer accounts.

Cigna also maintained a meaningful international health insurance business, providing coverage to globally mobile employees, expatriates, and local populations in select markets across Asia, Europe, the Middle East, and Africa. This international presence distinguished Cigna from purely domestic competitors and created a revenue stream that operated under different regulatory and competitive dynamics than the U.S. employer market. The international business served a niche that few competitors addressed comprehensively — global employers who needed consistent health coverage across multiple jurisdictions, with coordination of benefits, access to quality provider networks in diverse geographies, and administrative simplicity for HR departments managing employees stationed around the world. Companies like UnitedHealth Group (UNH) had some international presence, but none matched Cigna's combination of geographic reach and depth of service for the expatriate and globally mobile population.

During this period, Cigna's financial performance was steady but unspectacular relative to the managed care industry's largest players. UnitedHealth Group (UNH) was building Optum into a healthcare services empire that would eventually generate more revenue than many standalone Fortune 500 companies. Anthem (now Elevance Health, ELV) was consolidating Blue Cross Blue Shield plans and leveraging the Blue brand's recognition with consumers and providers. Aetna was expanding across commercial and government programs before its eventual acquisition by CVS Health (CVS) in a transaction that combined retail pharmacy, PBM, and insurance under one roof. Humana (HUM) was deepening its concentration in Medicare Advantage, riding the demographic wave of baby boomer aging into a growth trajectory that pure commercial insurers could not match. Cigna's employer focus provided stability and decent returns, but it did not produce the growth trajectory or market capitalization expansion that vertical integration or government program enrollment were generating for competitors.

Why did Anthem try to acquire Cigna (2015 - 2017)?

In 2015, Anthem announced a $54 billion bid to acquire Cigna, which would have created the largest health insurer in the United States by membership. The proposed merger was part of a broader consolidation wave — Aetna was simultaneously attempting to acquire Humana (HUM) — that would have reduced the major national insurers from five to three. The strategic logic was straightforward: scale in managed care produces lower per-member administrative costs, greater provider negotiating leverage, broader network reach, and the ability to spread technology and analytics investments across a larger membership base.

The relationship between the two companies during the merger process was notably contentious. Cigna's management, led by CEO David Cordani, expressed public concerns about Anthem's integration capabilities and the terms of the merger agreement. The acrimony was unusual for a proposed combination of this scale and signaled fundamental disagreements about governance, leadership, and strategic direction that went beyond normal merger negotiation friction. Cigna ultimately sued Anthem to terminate the merger agreement, alleging that Anthem had breached its obligations under the agreement — an extraordinary step that underscored the depth of the rift.

The merger collapsed in 2017 after the Department of Justice sued to block it on antitrust grounds. A federal judge agreed that the combination would substantially reduce competition in the market for health insurance sold to large national employers — precisely the segment where both Anthem and Cigna were strongest. The court found that the merger would give the combined entity disproportionate negotiating power with providers and employers in ways that could reduce competition and harm consumers. The Aetna-Humana merger was blocked by a different court for parallel reasons. The managed care industry's attempt at horizontal consolidation had reached a regulatory ceiling.

The failure was structurally informative beyond its immediate consequences. It demonstrated that the U.S. government would not permit the national health insurance market to consolidate from five major players to three, regardless of the efficiency arguments the companies advanced. The antitrust analysis focused specifically on the national accounts market — large employers who purchase health insurance for employees across multiple states — where Anthem and Cigna were the two largest competitors. This constraint shaped every subsequent strategic decision Cigna made. If horizontal growth through merger with a rival insurer was foreclosed, growth would need to come from somewhere else — from adjacent markets, from vertical integration, or from expanding the definition of what a health benefits company does. The clock was ticking: competitors were growing through channels Cigna could not access, and standing still meant structural decline in relative competitive position.

What did Cigna's $67 billion Express Scripts acquisition change (2018 - 2020)?

In March 2018 — less than a year after the Anthem merger collapsed — Cigna announced the acquisition of Express Scripts for approximately $67 billion. The speed of the pivot was itself structurally significant. Express Scripts was the largest independent pharmacy benefit manager in the United States, processing over a billion prescriptions annually and managing drug formularies for tens of millions of Americans across commercial employers, health plans, unions, and government programs. The acquisition transformed Cigna's revenue base overnight. Express Scripts generated more revenue than Cigna's legacy insurance operations, and the combined company's economic center of gravity shifted from health insurance underwriting to pharmacy benefit management and health services.

The strategic logic extended beyond revenue addition. Pharmacy spending was the fastest-growing component of healthcare cost, driven by specialty drug pricing, biologics, gene therapies, and an aging population with increasing medication needs. Specialty drugs — high-cost medications for complex conditions like cancer, autoimmune diseases, and rare genetic disorders — represented a small fraction of prescriptions but a rapidly growing share of total drug spending. Controlling the pharmacy benefit — formulary design, drug pricing negotiation, mail-order fulfillment, specialty pharmacy management, prior authorization — gave Cigna leverage over a cost category that its insurance business was already paying for. Instead of negotiating drug costs as one insurer among many, Cigna now operated the infrastructure that determined which drugs were covered, at what price, through which channels, and under what clinical criteria.

Express Scripts brought specific capabilities that complemented Cigna's insurance operations. Its formulary management expertise — the science and art of designing drug lists that balance clinical effectiveness, patient access, and cost control — was recognized as among the most aggressive in the industry. Express Scripts had been willing to exclude high-cost brand drugs from its formulary when lower-cost alternatives were available, using its purchasing volume as leverage to negotiate deeper discounts from pharmaceutical manufacturers. Its mail-order pharmacy operations provided a lower-cost dispensing channel than retail pharmacies. Its specialty pharmacy division managed the distribution and clinical support for the most expensive medications in the healthcare system. And its data analytics capabilities — built on billions of prescription transactions — enabled clinical interventions, fraud detection, and utilization management at a scale that few organizations could match.

Cigna consolidated its services businesses — including Express Scripts, behavioral health, care management, and analytics operations — under the Evernorth Health Services brand. The rebranding was not cosmetic. It signaled that Cigna viewed itself as two distinct but connected enterprises: Cigna Healthcare, which underwrote and administered health insurance for employers and individuals, and Evernorth, which provided pharmacy, care, and analytics services to Cigna's own members as well as to external clients including other insurers, employers, and government programs. Evernorth's ability to serve customers beyond Cigna's insurance membership base was structurally important — it meant the services business could grow independently of insurance enrollment, attracting clients who might compete with Cigna Healthcare in the insurance market but still valued Evernorth's pharmacy and services capabilities.

How did Evernorth become Cigna's dominant segment (2020 - 2023)?

Evernorth rapidly became the dominant segment of The Cigna Group's financial profile. Pharmacy revenues — driven by prescription volume, specialty drug management, and the economics of drug pricing intermediation — dwarfed the insurance segment's premium revenue. By the early 2020s, Evernorth was generating roughly two-thirds of the company's total revenue and a substantial majority of adjusted operating income. The structural transformation was complete: Cigna was, by economic weight, a healthcare services company that also operated a health insurance business — not the other way around. This reality was sometimes obscured by the company's continued categorization as a managed care organization, but the revenue and profit composition told a different story.

The economics of pharmacy benefit management are structurally distinct from health insurance underwriting and deserve detailed examination. PBMs earn revenue through multiple mechanisms that operate simultaneously. Administrative fees are charged per prescription processed or per member per month. Rebates are negotiated with pharmaceutical manufacturers — drug makers pay PBMs for favorable formulary placement that drives prescription volume toward their products, and a portion of these rebates is passed through to plan sponsors while a portion may be retained by the PBM. Spread pricing captures the difference between what a PBM charges the plan sponsor for a prescription and what it pays the dispensing pharmacy — a margin that varies by drug, pharmacy, and contract terms. Specialty pharmacy margins are earned on high-cost medications dispensed through the PBM's own pharmacy operations, where the markups on drugs costing tens of thousands of dollars per course of treatment can generate substantial absolute dollar margins. And mail-order pharmacy operations provide a lower-cost dispensing channel where the PBM captures both the dispensing margin and the convenience value that home delivery provides to patients with chronic conditions requiring regular refills.

These revenue streams create a business with high throughput, significant volume leverage, and margins that depend on negotiating position, formulary design, and the mix between generic, brand, and specialty drugs. The PBM model is, at its core, an intermediation business — it creates value by sitting between parties who need each other but cannot efficiently transact directly at scale. Pharmaceutical manufacturers need access to covered lives. Pharmacies need prescription volume. Employers and health plans need cost management. Patients need access to medications. The PBM connects all of these parties, and the complexity of the connections creates the opacity that generates margin. This structural characteristic — value derived from informational position rather than from producing a product — is what makes PBM economics both lucrative and politically vulnerable.

Evernorth's integration with Cigna Healthcare created operational linkages that neither business could produce independently. Medical and pharmacy data could be combined to identify patients whose drug regimens conflicted with their medical conditions, to detect dangerous drug interactions that would not be visible in either data set alone, to manage chronic disease through coordinated care and medication management, and to design benefit structures that steered utilization toward lower-cost alternatives without compromising clinical outcomes. A patient with diabetes, for example, could have their medical claims data from Cigna Healthcare linked to their prescription history from Evernorth to identify whether they were adhering to their medication regimen, whether their drug therapy was aligned with current clinical guidelines, and whether a lower-cost therapeutic alternative was available that would produce equivalent health outcomes at reduced cost to the employer and the patient.

These data linkages were the same structural logic that UnitedHealth Group (UNH) pursued through OptumRx and its broader Optum platform — vertical integration producing information advantages that standalone insurers or standalone PBMs could not replicate. However, the comparison with UnitedHealth's Optum was instructive in its differences. Optum encompassed physician practices employing tens of thousands of doctors, ambulatory surgical centers, home health services, a technology and analytics consulting business serving external health systems, and a financial services operation processing healthcare payments. This breadth of healthcare services infrastructure gave UnitedHealth presence across the care delivery value chain that Evernorth did not match. Cigna's vertical integration was narrower, concentrated on pharmacy and care management rather than extending into care delivery itself. Whether this narrower focus represented disciplined specialization — avoiding the complexity and capital intensity of physician employment and facility operations — or a structural limitation that left Cigna exposed to competitors with deeper integration remained an open question that the market debated continuously.

Why did Cigna pursue a Humana acquisition (2023 - 2024)?

In late 2023, reports emerged that Cigna was in advanced discussions to acquire Humana (HUM), a managed care company with deep concentration in Medicare Advantage. The proposed deal — which would have been valued at over $100 billion — represented an attempt to address Cigna's most significant structural gap: limited exposure to government health programs. While UnitedHealth Group (UNH) and Elevance Health (ELV) generated substantial revenue from Medicare Advantage and Medicaid managed care, Cigna's membership was predominantly commercial and employer-sponsored. The demographic arithmetic was unfavorable: the population aging into Medicare eligibility was growing faster than the working-age population that supports employer-sponsored insurance. Acquiring Humana would have added millions of Medicare Advantage members and repositioned Cigna as a major player in the government programs market, transforming its demographic exposure from a headwind into a tailwind.

The strategic rationale had a second dimension: combining Evernorth's PBM capabilities with Humana's Medicare Advantage membership would have created integrated pharmacy-insurance economics in the government program space that paralleled what Cigna had already built in the commercial employer market. Medicare beneficiaries consume a disproportionate share of prescription drugs — chronic conditions, polypharmacy, and the high cost of specialty medications for conditions prevalent in older populations make the pharmacy benefit particularly valuable in the Medicare context. Evernorth's drug pricing expertise applied to Humana's Medicare drug spend could, in theory, produce meaningful cost reduction and competitive advantage in Medicare Advantage bid pricing.

Cigna withdrew from the proposed transaction in December 2023, announcing instead a $10 billion share buyback program. The reasons for withdrawal were not publicly detailed in full, but the structural obstacles were apparent from multiple directions. Regulatory approval for a combination of this magnitude — in a political environment where healthcare consolidation faced bipartisan skepticism — was uncertain at best. The Federal Trade Commission under the Biden administration had adopted an aggressive posture toward large mergers, and a Cigna-Humana combination would have faced intense scrutiny over competitive effects in both the insurance and PBM markets. The integration complexity of merging two large managed care operations with fundamentally different customer bases, geographic footprints, provider network strategies, and operating systems would have been substantial and consumed years of management attention. And the price Humana's shareholders expected reflected a premium for Medicare Advantage growth that embedded assumptions about enrollment trends, reimbursement rate stability, and profit margins that were themselves under pressure as CMS adjusted Medicare Advantage payment formulas.

The abandoned Humana bid, combined with the earlier Anthem merger failure, established a clear structural pattern: Cigna's attempts at transformative horizontal consolidation with rival insurers have been consistently frustrated — by regulators in the Anthem case, by strategic complexity and financial considerations in the Humana case. This pattern reinforced the centrality of the Evernorth strategy. If Cigna could not grow by absorbing competitor insurers, its growth would continue to depend on expanding the pharmacy and health services business — through prescription volume growth, new service lines, biosimilar formulary management, specialty pharmacy expansion, and external client acquisition. The company's strategic degrees of freedom were narrower than they appeared from the outside, constrained by a regulatory environment that permitted vertical expansion but resisted horizontal combination at scale.

What does Cigna's bifurcated structure look like today (2024 - Present)?

The Cigna Group now operates as a bifurcated enterprise whose two halves serve different customers, face different competitive dynamics, and generate different economic profiles. Evernorth Health Services processes hundreds of millions of prescriptions annually, manages specialty pharmacy operations for some of the most expensive medications in the healthcare system, operates one of the largest mail-order pharmacy networks in the country, and provides behavioral health, care management, and data analytics services to a client base that extends well beyond Cigna Healthcare's insurance membership. Cigna Healthcare serves primarily large employer clients through administrative services contracts, with a smaller but significant fully-insured commercial business, a growing but still modest Medicare Advantage and government programs presence, and the distinctive international health services franchise.

The company's international health services business — covering expatriates, globally mobile employees, and select local populations — provides geographic diversification that none of its major domestic peers replicate at comparable scale. Operations span dozens of countries with coverage tailored to local regulatory environments and healthcare systems. This international franchise operates under different competitive conditions than the domestic business: fewer large-scale competitors, higher barriers to entry created by regulatory complexity and the need for multinational provider networks, and customer relationships that embed deeply into the human resources operations of global corporations. It remains a distinctive asset, though one that receives less analytical attention than the Evernorth and Cigna Healthcare segments — partly because it generates less revenue and partly because its dynamics are difficult to assess without specialized knowledge of international health insurance markets.

Cigna's structural position in the competitive landscape is specific and defensible, but bounded by the choices that created it. It is the only major managed care company whose largest business, by revenue, is pharmacy benefit management rather than insurance underwriting. It serves the employer market with depth and specialization that government-focused competitors do not match. But it lacks the breadth of healthcare services infrastructure that UnitedHealth Group (UNH) has built through Optum's care delivery operations — the physician practices, the surgical centers, the home health businesses, the technology consulting arm. And it lacks the government program enrollment base that provides demographic tailwinds to Humana (HUM) and Elevance Health (ELV). The structural choice to build around PBM economics rather than government programs or care delivery is a trade-off, not an unambiguous advantage — and the evolution of drug pricing regulation, biosimilar competition, PBM transparency requirements, and the shifting balance between employer-sponsored and government-funded health coverage will test whether that choice proves durable over the next decade.

Structural Patterns

Vertical Integration as Strategic Pivot — When horizontal consolidation with Anthem was blocked, Cigna pivoted to vertical integration through Express Scripts. This pattern — regulatory closure of one growth path forcing innovation along another — is a recurring dynamic in concentrated industries where antitrust enforcement constrains horizontal mergers but permits vertical combinations that restructure the value chain. The pivot was not merely strategic adaptation; it fundamentally changed what kind of company Cigna is.
PBM Economics as Revenue Center of Gravity — The Express Scripts acquisition shifted Cigna's economic core from insurance underwriting to pharmacy benefit management. Evernorth's prescription volume, rebate economics, specialty pharmacy margins, and mail-order dispensing operations now generate the majority of the company's revenue and operating income — making Cigna structurally more similar to a healthcare services intermediary than to a traditional health insurer, despite its continued classification as a managed care organization.
Employer-Focused Insurance as Differentiation — Cigna's concentration on large, self-funded employer accounts creates a customer base with higher switching costs, longer contract durations, and more sophisticated purchasing behavior than individual or small-group markets. This focus produces stability and margin predictability but limits the demographic tailwinds available to competitors with larger government program enrollment, where population aging drives structural membership growth independent of competitive dynamics.
Data Linkage Between Payer and Pharmacy — Combining medical claims data from Cigna Healthcare with pharmacy utilization data from Evernorth creates analytical capabilities for cost management, chronic disease intervention, drug interaction detection, and benefit design that neither business produces in isolation. This feedback loop mirrors the payer-services integration that UnitedHealth Group (UNH) pursues through Optum, though Cigna's version is narrower in scope — concentrated on pharmacy rather than spanning the full care delivery spectrum.
External Client Revenue as Growth Lever — Evernorth serves clients beyond Cigna Healthcare's membership — other insurers, self-funded employers, unions, and government programs that purchase pharmacy benefit management and care management services independently. This external revenue base allows Evernorth to grow without corresponding growth in Cigna's insurance enrollment, decoupling the services business from the insurance business's competitive dynamics and creating a platform that scales on prescription volume regardless of its source.
Blocked Mergers as Structural Constraint — The failed Anthem merger and abandoned Humana acquisition reveal a persistent constraint: regulators and market conditions resist large horizontal combinations among managed care companies. This structural ceiling on consolidation forces growth through vertical integration, organic expansion, or international diversification rather than through absorption of domestic insurance rivals — a constraint that does not apply equally to all competitors and that shapes Cigna's strategic options in ways the market does not always price accurately.

Key Turning Points

1982: Formation of Cigna — The merger of Connecticut General and INA Corporation created the Cigna name and combined life, health, and property-casualty insurance under one entity. This consolidation provided scale but also saddled the company with diversified insurance lines of varying profitability — including property-casualty liabilities from asbestos and environmental claims that would take years and billions of dollars to resolve. The formation set in motion the long process of strategic narrowing — shedding non-core businesses one by one — that would eventually produce a health-benefits-focused enterprise.

2017: Anthem Merger Blocked — The federal court ruling that prevented Anthem from acquiring Cigna closed the path of horizontal consolidation and forced Cigna's leadership to find alternative growth strategies. This turning point was as much about what it foreclosed as what it immediately produced. The ruling established that the national employer health insurance market would not be allowed to consolidate further among the largest players. Within a year, Cigna had announced the Express Scripts acquisition — a vertical integration move that would not have been conceived, let alone pursued, if horizontal consolidation had succeeded in creating the largest insurer in the country.

2018: Express Scripts Acquisition — The $67 billion purchase of Express Scripts was the defining transaction of modern Cigna. It restructured the company's revenue base, created the Evernorth platform, and repositioned Cigna from a mid-tier managed care insurer into the owner of the largest independent PBM in the United States. The acquisition did not merely add pharmacy benefit management to Cigna's capabilities — it made pharmacy benefit management the company's primary business by revenue and profit contribution. Every subsequent strategic decision — the Evernorth branding, biosimilar formulary strategies, specialty pharmacy investments, external client growth — flows from this single acquisition and the structural transformation it produced.

2023: Humana Bid Abandoned — Cigna's withdrawal from the proposed Humana acquisition confirmed that horizontal consolidation remained structurally foreclosed — this time not by regulators but by the complexity and cost of the transaction itself. The decision to pursue a $10 billion share buyback instead signaled that Cigna's leadership viewed organic growth, capital return, and continued Evernorth expansion as more viable paths than transformative M&A in the insurance segment. The withdrawal left Cigna's government program exposure gap unaddressed and reinforced Evernorth's centrality to the company's growth thesis for the foreseeable future.

2024: Biosimilar and Specialty Pharmacy Expansion — Evernorth's strategic investments in biosimilar access programs and specialty pharmacy capabilities positioned Cigna at the intersection of the pharmaceutical industry's most significant cost and competition dynamics. As patent expirations on major biologic drugs — including blockbuster medications for autoimmune conditions, cancer, and other chronic diseases — opened pathways for lower-cost biosimilar alternatives, Evernorth's formulary control and distribution infrastructure created opportunities to accelerate biosimilar adoption, capture the margin spread between biologic and biosimilar pricing, and demonstrate value to plan sponsors through measurable drug cost reduction. This structural evolution has the potential to reshape PBM economics by creating new sources of value as the pharmaceutical landscape shifts from branded biologic dominance toward biosimilar competition.

Risks and Fragilities

The most immediate structural fragility facing The Cigna Group is political and regulatory pressure on pharmacy benefit management. PBMs have become a focal point of bipartisan scrutiny over drug pricing — criticized by pharmaceutical manufacturers for opaque rebate practices that allegedly inflate list prices, by independent pharmacies for reimbursement rates and contract terms that threaten their economic viability, by employers for retaining rebate dollars that could reduce plan costs for employees, and by patients for copay structures that may be calculated on list prices rather than net prices that reflect negotiated discounts. Congressional hearings have featured executives from the three largest PBMs — Express Scripts/Evernorth, CVS Caremark, and OptumRx — testifying about practices that legislators on both sides of the aisle characterize as contributing to the drug pricing crisis. State-level PBM transparency laws have proliferated, imposing varying disclosure requirements and practice restrictions. Federal Trade Commission investigations have examined whether PBM practices constitute unfair methods of competition. If federal legislation mandates full rebate pass-through to the point of sale, eliminates spread pricing, requires PBMs to operate under fiduciary standards, or fundamentally restructures how PBMs are compensated, the economic model that generates Evernorth's margins could be materially altered in ways that would require significant business model adaptation.

Concentration risk within the Evernorth business model deserves examination. The PBM business depends on maintaining large prescription volumes across a broad client base — volume that provides negotiating leverage with pharmaceutical manufacturers and pharmacies. Client losses — particularly large employer or health plan accounts that represent significant prescription volume — can reduce Evernorth's purchasing power in ways that affect rebate negotiations, pharmacy network terms, and operating leverage across the fixed-cost infrastructure of mail-order pharmacies and specialty pharmacy operations. The competitive landscape includes two other major PBMs — CVS Caremark (part of CVS Health, CVS) and OptumRx (part of UnitedHealth Group, UNH) — that together with Evernorth control the vast majority of prescription volume in the United States. This oligopoly structure has itself drawn regulatory attention and could face structural remedies if political sentiment shifts toward requiring PBM separation from insurers or mandating market structure changes. Additionally, emerging transparent PBM models and direct-to-consumer pharmacy operations challenge traditional PBM economics from different structural positions — offering employers visibility into actual drug costs and PBM margins that the traditional model does not provide.

Cigna Healthcare's limited exposure to government health programs creates a demographic vulnerability that compounds over time. Medicare Advantage enrollment is growing as the baby boomer generation ages into Medicare eligibility — a demographic trend that will continue for years as the largest generation in American history moves through the Medicare-eligible age range. Medicaid managed care is expanding as states seek cost containment through private administration and as eligibility thresholds adjust. Competitors with substantial government program enrollment — UnitedHealth Group (UNH), Humana (HUM), Elevance Health (ELV) — benefit from population aging as a structural growth driver that operates independently of economic cycles, employer decisions, or competitive wins and losses. Cigna's employer-focused model ties its insurance revenue to corporate benefits spending, which correlates with employment levels, wage growth, employer decisions about benefit generosity, and the competitive dynamics of the large employer insurance market. These are cyclical and competitive variables, not demographic certainties. The abandoned Humana acquisition would have addressed this gap by adding millions of Medicare Advantage members to Cigna's enrollment base; its withdrawal leaves the demographic vulnerability unresolved and potentially unresolvable through large-scale M&A given the structural constraints on horizontal consolidation.

The integration between Evernorth and Cigna Healthcare, while strategically logical, creates internal complexity that can produce misalignment and governance challenges. Transfer pricing between segments — how Evernorth charges Cigna Healthcare for pharmacy services, how the economics of shared clients are allocated between segments, how investment decisions are prioritized when both segments compete for capital — affects reported segment profitability and can create incentive conflicts that are difficult to resolve transparently. When the PBM and the insurer share corporate ownership, the question of whether formulary decisions are optimized for patient outcomes, plan sponsor costs, or Evernorth margins becomes a matter of internal governance rather than market negotiation. External clients — health plans and employers that purchase Evernorth's services while competing with Cigna Healthcare for members — may question whether Evernorth provides equivalent service quality, pricing, and data access to non-Cigna clients as it does to Cigna Healthcare's own members. This conflict-of-interest concern mirrors the scrutiny UnitedHealth Group (UNH) faces regarding Optum's relationship with UnitedHealthcare, and it creates a persistent tension that management must navigate without the benefit of arm's-length market discipline between the two businesses.

The international health services business, while distinctive and competitively differentiated, introduces geopolitical and currency risk that the domestic business does not face. Operations across dozens of countries subject Cigna to varying regulatory regimes — each with its own rules governing insurance pricing, coverage mandates, claims handling, and capital requirements. Political instability in certain markets can disrupt operations or make it difficult to collect premiums and pay claims. Foreign exchange fluctuations — particularly movements in the U.S. dollar relative to the currencies in which international premiums are collected and claims are paid — can compress reported margins when international results are translated back to U.S. dollars. The international business is relatively small compared to Evernorth and Cigna Healthcare, which limits its ability to offset domestic challenges but also means that international disruptions have bounded impact on the consolidated enterprise. The structural value of the international franchise lies less in its profit contribution than in the optionality it provides — the ability to grow in markets where U.S. competitive dynamics and regulatory constraints do not apply.

What Investors Can Learn

Regulatory constraints shape strategic direction — Cigna's pivot from horizontal consolidation to vertical integration was not a free strategic choice but a forced response to antitrust enforcement that closed one path and opened another. Understanding what regulators will and will not permit — and how those boundaries shift with political cycles — is as important to understanding a company's trajectory as understanding what management intends. The structural ceiling on horizontal mergers in managed care fundamentally altered Cigna's identity.
Revenue composition reveals structural identity — Cigna's stock trades as a managed care company and sits in managed care indices, but its revenue is predominantly generated by pharmacy benefit management and healthcare services. The structural identity of a company — what it actually earns money doing — can diverge significantly from its industry classification, and that divergence affects which risks and opportunities are most material. Analyzing Cigna as a health insurer misses the PBM dynamics that drive the majority of its economics.
Vertical integration creates advantages and conflicts simultaneously — Combining insurance with pharmacy benefit management produces data linkages, cost management capabilities, and cross-selling opportunities that standalone entities cannot replicate. But it also creates internal transfer pricing complexity, conflict-of-interest scrutiny from external clients, and governance challenges that vertically separated competitors avoid entirely. The net effect of vertical integration depends on execution quality, regulatory tolerance, and the ability to maintain trust with external clients who are also competitors.
Customer concentration determines growth ceiling shape — Cigna's employer focus produces stable, high-switching-cost relationships with sophisticated buyers who value demonstrable cost management. But it limits access to the demographic growth that government programs provide as population aging shifts healthcare spending from employer-sponsored to government-funded coverage. The shape of a company's growth ceiling — whether it is constrained by customer segment, regulatory barriers, or addressable market size — determines long-term trajectory as much as current performance metrics.
Failed transactions reveal as much as completed ones — The blocked Anthem merger and abandoned Humana acquisition are not merely historical footnotes. They define the structural boundaries within which Cigna operates and explain why the company's strategy emphasizes Evernorth expansion over insurance consolidation. What a company tried and could not do is often as informative as what it accomplished — the pattern of failed attempts reveals the constraints that shape the possible.
PBM economics are structurally exposed to transparency demands — The pharmacy benefit management business model generates value from informational intermediation — sitting between drug manufacturers, pharmacies, employers, and patients in ways that create margin from complexity and opacity. As transparency regulation increases, as congressional scrutiny intensifies, and as alternative pharmacy models emerge that offer direct-to-consumer or pass-through pricing, the durability of traditional PBM economics faces a structural test that prescription volume growth alone cannot resolve. The question is not whether PBM regulation is coming but how much margin compression it will produce.

Inside CompanyGraph

View this perspective inside CompanyGraph.